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Abstract
Amyotrophic lateral sclerosis (ALS) is the most frequent adult-onset motor neuron disease, and recent evidence has
suggested that endoplasmic reticulum (ER) stress signaling is involved in the pathogenesis of ALS. Here we identified a small
molecule, SUN N8075, which has a marked protective effect on ER stress-induced cell death, in an in vitro cell-based
screening, and its protective mechanism was mediated by an induction of VGF nerve growth factor inducible (VGF): VGF
knockdown with siRNA completely abolished the protective effect of SUN N8075 against ER-induced cell death, and
overexpression of VGF inhibited ER-stress-induced cell death. VGF level was lower in the spinal cords of sporadic ALS
patients than in the control patients. Furthermore, SUN N8075 slowed disease progression and prolonged survival in mutant
SOD1 transgenic mouse and rat models of ALS, preventing the decrease of VGF expression in the spinal cords of ALS mice.
These data suggest that VGF plays a critical role in motor neuron survival and may be a potential new therapeutic target for
ALS, and SUN N8075 may become a potential therapeutic candidate for treatment of ALS.
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Introduction
In chronic neurodegenerative disorders such as Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease (HD), and
amyotrophic lateral sclerosis (ALS), abnormally unfolded proteins
are known to aggregate and accumulate in neurons, and these
proteins are thought to be closely related to the initiation and
development of these neurodegenerative diseases [1,2,3]. Recent
studies suggest that endoplasmic reticulum (ER) stress plays a role
in the pathogenesis of familial and sporadic ALS [4,5,6]. A variety
of conditions such as environmental and genetic causes that cause
unfolded or misfolded proteins in the ER can activate the ER
stress response although the cell normally survives the insult.
However, excessive or prolonged ER stress can induce cell death,
usually in the form of apoptosis. In familial ALS model mice
carrying the mutant SOD1 gene, mutant superoxide dismutase-1
forms aggregates in the ER have been reported to induce the
expression of 78 kDa glucose-regulated protein (GRP78/BiP), an
ER resident molecular chaperone, and to activate caspase-12,
leading to neuronal cell death [7,8]. Furthermore, Ilieva et al. [6]
have reported increased ER chaperones such as protein-disulfide
isomerase (PDI) and phosphorylation of eukaryotic initiation factor
2a (eIF2a) in spinal cords from patients with sporadic ALS. Thus,
although the etiologies such as the responsible genes or
environmental factors are different for familial and sporadic
ALS, they may have a common mechanism for neuronal cell
death through ER stress as downstream signaling pathways.
Despite many clinical trials for treatment of ALS, there has been
little success in the search for neuroprotective agents. Therefore,
we screened for protecting cells from ER stress, and identified a
small molecule, SUN N8075 (Fig. 1A). SUN N8075 has been
reported to have a potent antioxidant property [9], and is
currently in a phase I clinical trial for stroke. In the present study,
we demonstrated that SUN N8075 induces VGF nerve growth
factor inducible (VGF) as a mechanism for protecting ER stress-
induced cell death in an antioxidant-independent manner. VGF is
a neuronal polypeptide first identified as a cDNA clone from plate
V of the nerve growth factor (NGF)-induced rat pheochromocy-
toma (PC12) cell cDNA library [10]. VGF is widely expressed in
neurons in the brain and involved in maintaining organism energy
balance, as well as in mediating hippocampal synaptic activity
[11,12]. Interestingly, a recent study reported that VGF content
was decreased in the cerebrospinal fluid (CSF) of ALS patients and
in the serum, CSF and spinal cord motor neurons of G93A mice
[13]. These findings strongly suggest that a VGF inducer, SUN
N8075, may become a potential therapeutic candidate for ALS. In
the present study, we demonstrated that (i) VGF is involved in the
protective effects of SUN N8075 on ER stress-induced cell death
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15307Figure 1. SUN N8075 protects against ER stress-induced cell death and attenuates cleaved caspase-3 production. (A) Chemical
structure of SUN N8075, (B) Representative phase-contrast microscopy showing the effect of SUN N8075 on morphological changes in SH-SY5Y cells
after tunicamycin at 2 mg/ml. Bar =50 mm. (C, D) Cell damage was induced by tunicamycin (2 mg/ml) or thapsigargin (2 mM), and cell viability was
measured with the tetrazolium salt (WST-8) reduction test. SUN N7085 or vehicle was applied 1 h before the tunicamycin or thapsigargin treatment.
Each column represents the mean 6 S.E.M. (n=8). ##p,0.01 versus control. **p,0.01 versus tunicamycin or thapsigargin alone. (E) Representative
fluorescence microscopy showing nuclear stainings for Hoechst 33342 (blue) and YO-PRO-1 (green) at 24 h after the addition of 2 mg/ml of
tunicamycin with or without SUN N8075. Each column represents the mean 6 S.E.M. (n=6). ** and ##p,0.01 versus relevant control group.
(F) Tunicamycin increased cleaved caspase-3, and treatment with SUN N8075 inhibited the increase of cleaved caspase-3 after tunicamycin. Each
column represents the mean 6 S.E.M. (n=6). #p,0.05 versus control. **p,0.01 versus tunicamycin alone.
doi:10.1371/journal.pone.0015307.g001
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prolongs survival in familial ALS models involving ER stress.
Materials and Methods
Chemicals
(2S)-1-(4-Amino-2,3,5-trimethylphenoxy)-3-{4-[4-(4-fluoroben-
zyl) phenyl]-1-piperazinyl}-2-propanol dimethanesulfonate (SUN
N8075) was synthesized at Asubio Pharma Co. Ltd. (Osaka,
Japan).
Cell cultures
Cultures of human neuroblastoma (SH-SY5Y) cells were
maintained in Dulbecco’s modified Eagles’s medium (D-MEM,
St. Louis, MO) containing 10% FBS (Valeant, Costa Mesa, CA),
100 U/ml penicillin (Meiji Seika Kaisha Ltd., Tokyo, Japan), and
100 mg/ml streptomycin (Meiji Seika Kaisha Ltd.) in a humidified
atmosphere of 95% air and 5% CO2 at 37uC. The cells were
passaged by trypsinization every 5 to 7 days, as described in a
previous report [14].
ER stress-induced cell death
To examine the effects of the SUN N8075 on tunicamycin-
induced cell death, cells were seeded at a density of 1610
4 cells per
well into 96-well plates, and then incubated in a humidified
atmosphere of 95% air and 5% CO2 at 37uC for 2 days.
Tunicamycin (Wako, Osaka, Japan) or thapsigargin was added to
the cells at a final concentration of 2 mg/ml and 2 mM,
respectively. SUN N8075 was added 1 h before the tunicamycin
treatment, at which time the cell-culture medium was replaced
with D-MEM containing 1% FBS. Assessment of cell viability was
performed using two methods, each at 24 h after the addition of
tunicamycin. The first method was a single-cell digital imaging-
based method employing fluorescent staining of nuclei. Cell death
was assessed on the basis of combination staining with fluorescent
dyes [namely, Hoechst 33342 and YO-PRO-1 (Molecular Probes,
Eugene, OR)], observations being made using an OLYMPUS
IX70 inverted epifluorescence microscope (OLYMPUS, Tokyo,
Japan). Hoechst 33342 freely enters living cells and therefore stains
the nuclei of viable cells, as well as those that have suffered
apoptosis or necrosis. Apoptotic cells can be distinguished from
viable and necrotic cells on the basis of nuclear condensation and
fragmentation. YO-PRO-1 is a membrane-impermeant dye that is
generally excluded from viable cells, whereas early-stage apoptotic
and necrotic cells are YO-PRO-1-positive. At the end of the
culture period, Hoechst 33342 and YO-PRO-1 dyes were added
to the culture medium (at 8 and 0.1 mM, respectively) for 30 min.
Images were collected using a digital camera (COOLPIX 4500,
Nikon, Tokyo, Japan). In a blind manner, a total of at least 400
cells per condition were counted using image-processing software
(Image-J ver. 1.33f; National Institutes of Health, USA). As the
second method for measuring cell viability, cell metabolic activity
was quantitatively assessed. Cell viability was assessed following
immersion in 10% WST-8 solution [2-(2-methoxy-4-nitrophenyl)-
3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monoso-
dium salt] with an electron carrier, 1-Methoxy PMS (1-
Methoxy-5-methylphenazinium, methyslsulfate) (Cell Counting
Kit-8, Dojin Kagaku, Kumamoto, Japan) for 3 h at 37uC, and
absorbance was recorded at 450 nm [15]. WST-8 is bioreduced by
cellular dehydrogenases to an orange formazan product that is
soluble in cell culture medium. The amount of formazan produced
is directly proportional to the number of living cells. This
absorbance is expressed as a percentage of that in control cells,
after subtraction of background absorbance.
Immunoblotting
SH-SY5Y cells or mouse spinal cords were lysed using a cell-
lysis buffer [RIPA buffer (R0278; Sigma) with protease (P8340;
Sigma) and phosphatase inhibitor cocktails (P2850 and P5726;
Sigma), and 1 mM EDTA]. Lysates were solubilized in SDS-
sample buffer, separated on 10% SDS-polyacrylamide gels, and
transferred to PVDF membrane (Immobilon-P; Millipore, Bed-
ford, MA). Transfers were blocked for 1 h at room temperature
with 5% Blocking One-P (Nakarai Tesque, Inc., Kyoto, Japan) in
10 mM Tris-buffered saline with 0.05% Tween 20 (TBS-T), then
incubated overnight at 4uC with the primary antibody. The
transfers were then rinsed with TBS-T and incubated for 1 h at
room temperature in horseradish peroxidase goat anti-rabbit or
goat anti-mouse (Pierce, Rockford, IL) diluted 1:2000. The
immunoblots were developed using chemiluminescence (Super
SignalH West Femto Maximum Sensitivity Substrate; Pierce), and
visualized with the aid of a digital imaging system (FAS-1000;
TOYOBO CO., LTD, Osaka, Japan). The primary antibodies
used were as follows: mouse anti-cleaved caspase-3 (#9661, Cell
Signaling, Beverly, MA), rabbit anti-VGF (SantaCruz, Santa
Cruz, CA) and rabbit anti-b-actin (clone AC-74, Sigma-Aldrich,
Saint Luis, MO).
Real-time PCR
To examine the effect of SUN N8075 on VGF mRNA
expression, SH-SY5Y cells were seeded in 96-well plates at a
density of 1.0610
4 cells per well. After the cells had been
incubating for 48 h, they were exposed to tunicamycin at 2 mg/ml
with or without SUN N8075 at 3 mM in 1% FBS DMEM for 2, 6,
or 12 h. Quantitative real-time PCR was performed using a
Thermal Cecler Real Time System (TP-800, Takara) with a
TaqManH Gene Expression Cells-to-CT
TM Kit (Applied Biosys-
tems) according to the manufacturer’s protocol. mRNA expression
was measured by real-time PCR using TaqMan probe (TaqMan
Gene Expression Assay): VGF (Assay ID Details: Hs00705044_s1).
The thermal cycler conditions were as follows: 2 min at 50uC and
then 10 min at 95uC, followed by two-step PCR for 50 cycles
consisting of 95uC for 15 sec followed by 60uC for 1 min. For each
PCR, we obtained the slope value, R2 value, and linear range of a
standard curve of serial dilutions. The results are expressed relative
to the GAPDH (#4333764T, Applied Biosystems) internal
control.
VGF knockdown and overexpression
For VGF knockdown, the following siRNA sequences specific to
human VGF were used: 59-AUUCACUCGGGUCAGCGU-
GUGCGUG-39 (sense), 59-CACGCACACGCUGACCCGAGU-
GAAU-39 (antisense). Stealth
TM RNAi Negative Control Medium
GC Duplex #2 was used as a control. All siRNAs were obtained
from Invitrogen (Carlsbad, CA, USA). The SH-SY5Y cells were
transfected with 50 pg of siRNA using Lipofectamine
TM RNAi
MAX Reagent (Invitrogen) according to the manufacturer’s
protocol.
For overexpression of VGF, pCMV6-ENTRY containing myc-
tagged VGF and same empty vector (control) were obtained from
ORIGENE (Rockville, MD, USA). SH-SY5Y cells were tran-
siently transfected with each plasmid using Lipofectamine
TM2000
(Invitrogen) according to the manufacturer’s protocol. The
transfected cells were subjected to immunoblot analysis and cell
death assay. The cells transiently transfected with plasmids or
siRNAs were incubated for 24 h at 37uC in a humidified
atmosphere of 95% air and 5% CO2.
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We used two types of transgenic animals overexpressing
mutated human SOD1 genes: transgenic mice overexpressing
mutated (glycine to alanine in position 93) human SOD1 (G93A)
[16] and transgenic rats overexpressing mutated (histidine to
arginine in position 46) human SOD1 (H46R) [17]. The
transgenic G93A [B6SJL-Tg (SOD1-G93A) 1Gur/J] mice were
purchased from the Jackson Laboratory (Bar Harbor, ME, USA).
The hemizygous SOD1G93A mice were maintained by mating
transgenic males with wild-type (WT) females. Mouse genotypes
were determined by polymerase chain reaction analysis as
previously reports [16,18]. The transgenic male H46R rats were
used a colony generated in Tohoku University Graduate School of
Medicine as a previous report [17]. All experiments were
approved and monitored by the Institutional Animal Care and
Use Committee of Gifu Pharmaceutical University (Permit
Number: 08-085, 2008-366).
Drugs
SUN N8075 was dissolved in 6% captisol solution, and
subcutaneously administered at doses of 30 mg/kg and 10 mg/
kg, respectively, once daily from 10-weeks-old (for SOD1G93A
mice) or 15-weeks-old (for SOD1H46R rat) to lifetime. In control
group, vehicle (6% captisol solution) was subcutaneously admin-
istered at 10 ml/kg.
Rotarod test
A rotarod test was performed with a rotation at 5 rpm once
every 7 days, as previously described by Chiba et al. [19]. Mice,
which did not learn to remain on the rod for 600 s, were excluded
from motor performance analysis. The disease onset was defined
as the day when a mouse first dropped off the rotarod within
600 s.
Motor score
Symptomatic disease onset and post-symptomatic disease
progression were assessed using a 5-point motor score system as
described in previous reports [20]. This assay was performed once
per day until the disease end-point. Rats were allowed to move
freely in open field and were scored blindly by a single observer
(H.T.). The scoring system was used following these scales: 5,
normal movement; 4, limping or dragging of any limb, however
still able to stand on hindlimbs; 3, dragging of lower body and
inability to stand on hindlimbs; 2, Unable to drag the lower body,
however righting reflexes present from both side; 1, a righting
reflex from only one side; 0, absent righting reflexes from both
sides within 30 second. This point was defined as the end-point
and lifespan was determined by the age of the rats at end-point.
Symptomatic onset was identified when the score showed 4.
Survivals
Mortality was scored at the day when the mouse was unable to
right itself within 30 s after being placed on its back.
Microarray analysis
Total RNA was extracted from SH-SY5Y using the RNeasy
Mini kit (Qiagen, Westburg, Leusden, NL, USA) including a
DNase digestion step, according to the manufacturer’s instruc-
tions. Total RNA was amplified and labeled with Cyanine 3 for
the test sample using Agilent’s Low RNA Input Linear
Amplification Kit (Agilent Technologies, Palo Alto, CA) following
the detailed protocol described in the kit manual (version 5.7).
Briefly, 500 ng of total RNA was reversed transcribed to double-
strand cDNA using a poly dT-T7 promoter primer. Primer,
template RNA and quality-control transcripts of known concen-
tration and quality were first denatured at 65uC for 10 min and
incubated for 2 hours at 40uC with 56first strand Buffer, 0.1 M
DTT, 10 mM dNTP, MMLV RT, and RNase-out. The MMLV-
RT enzyme was inactivated at 70uC for 15 min. cDNA products
were then used as templates for in vitro transcription to generate
fluorescent cRNA. cDNA products were mixed with a transcrip-
tion master mix in the presence of T7 RNA polymerase and Cy3
labeled-CTP and incubated at 40uC for 2 h. Labeled cRNAs were
purified using Qiagen’s RNeasy mini spin columns and eluted in
30 mL of nuclease-free water. After amplification and labeling,
cRNA quantity and cyanine incorporation were determined using
a NanoDrop ND. Microarray expression experiments were
performed on 4644 K Agilent Human and Mouse expression
arrays (Agilent technologies) by hybridizing SH-SY5Y cells
according to the manufacturer’s instructions. Images of the arrays
were acquired using a microarray scanner G2565BA (Agilent
technologies) and image analysis was performed using Feature
Extraction software version 9.5 (Agilent Technologies).
Gene expression data analyses (statistical analysis and
hierarchical clustering analysis)
Raw data was imported into GeneSpring GX 7.3.1 (Agilent
Technologies) and normalized by setting all measurements ,0.01
to 0.01, normalizing each chip to the 75th percentile of all
measurements taken for that chip, and normalizing each gene to
the median measurement for that gene across all chips. To focus
on genes with reliable measurements, the normalized data were
filtered for data that had present call in $33% of all samples
(based on flag information of Agilent Feature Extraction Software
v.9.5.3) and the genes chosen by parametric test (don’t assume
variances equal) with a Bejamini and Hochberg false discovery
rate (FDR) ,0.01 and twofold restriction filters were utilized.
Hierarchical clustering was performed on the log transformed
normalized data of all the samples. Pearson’s correlation was used
for the similarity metric and the calculation result was visualized
using ‘‘Gene Tree’’ algorism. A red/blue color scheme was used in
the heat maps of the gene expressions.
Tissue Preparation
SOD1G93A and WT mice at 14 weeks of age (decreasing motor
function) were anesthetized with sodium pentobarbital (80 mg/kg,
i.p.) (Nembutal, Dainippon, Osaka, Japan) and perfused with 2%
(w/v) paraformaldehyde solution in 0.01 M phosphate-buffered
saline (PBS) at pH 7.4. Spinal cord tissues were removed after a 15-
min perfusion at 4uC and immersed in the same fixative solution for
24 h. Each spinal cord included L1, L2, and L3 levels, were soaked
in 25% (w/v) sucrose at 4uC for 1 day, and then frozen in
embedding compound (Tissue-Tek, Sakura Finetechnical Co. Ltd.,
Tokyo, Japan). Embedded tissues were immediately frozen with
liquid nitrogen and stored at 280uC. Serial transverse sections were
cut on a cryostat to a thickness of 20 mm at 2-mm intervals (3
sections total for each segment) and used for cresyl violet staining or
immunohistochemistry.
Human spinal cord
Spinal cord segments were taken at autopsy from ten patients
with features typical of sporadic ALS. Spinal cord tissue from 6
individuals without history/evidence of neurological or psychiatric
disease was taken for the control samples (Table S1). Three
paraffin-embedded coronal sections cut at 4-mm thickness through
the spinal cord [cervical spinal cord (C7), thoracic spinal cord (T8),
VGF Inducer Prolongs Survival in ALS Model Animals
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manner. The research protocol was approved by the institutional
ethics committee of Niigata University, and informed consent was
obtained from all participants.
Immunohistochemistry
The sections were stained with the following antibodies: (i)
mouse anti-VGF monoclonal antibody (1:50; Santa Cruz
Biotechnology, Santa Cruz, CA, USA); (ii) goat anti-NeuN
polyclonal antibody (1:5000; Millipore, Bedford, MA, USA); (iii)
mouse anti-GFAP monoclonal antibody (1:1000; Millipore); and
(iv) mouse anti-CD11b monoclonal antibody (1:1000; BMA
Biomedicals, Augst, Switzerland) within Can Get Signal immu-
nostain solution A (Toyobo CO., LTD., Osaka, Japan). Sections
were treated with 0.3% H2O2 in methanol for 30 min at room
temperature and blocking with mouse-on-mouse blocking reagent
for 1 h at room temperature. Anti-VGF antibody was applied to
the sections for overnight at 4uC. After washing the sections with
0.01 M PBS, sections were incubated with biotinylated anti-mouse
IgG for 2 h followed by washing, and were incubated with the
avidin-biotin-peroxidase complex for 30 min at room tempera-
ture. The sections were finally visualized using diamino benzidine/
H2O2 substrate for peroxidase (Vector Laboratories, Inc.,
Burlingame, CA).
For paraffin embedding human spinal cord sections, conven-
tional antigen retrieval method for each antigen was performed at
its optimal condition with 0.01 M sodium citrate buffer, pH 7.4.
Next, coronal sections of spinal cord were washed with 0.01 M
PBS, and then treated with 0.3% hydrogen peroxidase in 0.01 M
PBS for 30 min at room temperature. Furthermore, the sections
were preincubated with 10% normal horse serum (Vector) in
0.01 M PBS for 30 min and then incubated for 1 h at room
temperature with specific goat anti-VGF polyclonal antibody (R-
15; 1:50, Santa Cruz Biotechnology, CA, USA) in the following
solution: 10% normal horse serum in 0.01 M PBS containing
0.3% (v/v) Triton X-100. They were washed with 0.01 M PBS
and then incubated with biotinylated anti-goat IgG before being
incubated with the avidin-biotin-peroxidase complex for 30 min at
room temperature, and finally visualized using diamino benzi-
dine/H2O2 substrate. To assess intensity of VGF immunoreactiv-
ity in the Rexed laminae IX anterior horn (AH) in the human
spinal cord, sections immunostained with VGF were used for the
intensity measurement: C7, T8, and L4 in the spinal cords of the
control patients and patients with sporadic ALS, respectively. The
volume used for the intensity measurement was 438633064 mm
(section thickness) of each side in the spinal cord. The density
measurements were carried out under objective 640 with bright-
field microscope in a masked fashion by a single observer (Y.I.).
Anti-VGF antibody revealed the expression pattern of VGF in
spinal cord. The density on each section was measured using
MetaMorph software (Molecular Devices). Data from each section
was averaged for each spinal cord, and the values obtained were
used to evaluate the density of VGF immunoreactivity.
When double-immunostaining for VGF/GFAP, VGF/NeuN,
or VGF/CD11b were performed, these antibodies were applied to
the sections for overnight at 4uC after blocking with 0.01 M PBS
containing 10% normal goat serum (Vector) or mouse-on-mouse
blocking reagent (M.O.M. immunodetection kit, Vector) for 1 h.
After washing the sections with 0.01 M PBS, immunoreactivity
was visualized by incubating them for 2 h at room temperature
with secondary antibodies conjugated with Alexa 488 rabbit anti-
mouse, Alexa 546 rabbit anti-goat, Alexa 488 goat anti-rabbit, or
Alexa 546 goat anti-mouse (1:1000; Invitrogen Japan K.K.,
Tokyo, Japan). At the end of immunostaining, Hoechst 33342
(1:1000) was added to the samples for 30 min to visualize nucleus.
Total images of the spinal cord were taken using a microscope
(BX50; Olympus, Tokyo, Japan) fitted with 620 and 640
microscope objective lenses. The images visualized by diamino
benzidine were taken using a charge-coupled device camera
(MicroPublisher 5.0RTV, QIMAGING, Burnaby, BC, Canada)
and immunofluorescence images were taken using a cooled
charge-coupled device camera (DP30BP; Olympus) at
136061024 pixels via Metamorph (Universal Imaging Corp.,
Downingtown, PA, USA).
Data Analysis
Data are presented as means 6 S.E.M. Statistical comparisons
were made by Dunnet’s test, Tukey test, or Student’s t-test using a
SPSS 16.0 (SPSS Inc., IL, USA). Statistical analysis of the
cumulative probability of survival was performed with the
Kaplan–Meier life test. Statistical analysis of the mean age of
onset and survival was performed with log-rank test. A value of
P,0.05 was considered to indicate a statistical significance.
Further Materials and Methods used in the supplemental
Figures and Tables were described in the supporting information
(Methods S1).
Results
SUN N8075 protects against cell death induced by ER
stress
Representative photographs in cell morphology occurring 24 h
after tunicamycin treatment at 2 mg/ml are shown in Fig. 1B. An
increase in non-adherent cells was observed at 24 h after
tunicamycin treatment compared with that in non-treated control
cells. Pretreatment with SUN N8075 at 10 mM reduced the
increase in non-adherent cells. SUN N8075 at 0.3 to 10 mM
concentration-dependently inhibited the reduction of cell viability
24 h after tunicamycin treatment, its effect being significant at 1, 3
and 10 mM (Fig. 1C). Furthermore, SUN N8075 at 0.3 to 3 mM
concentration-dependently inhibited the reduction of cell viability
24 h after thapsigargin treatment, and its effect being significant at
1 and 3 mM (Fig. 1D). Next, we evaluated cell death using
fluorescence stainings of nuclei with Hoechst 33342 and YO-
PRO-1 dyes (Fig. 1E). Non-treated control cells displayed normal
nuclear morphology and negative staining with YO-PRO-1 dye,
which stains early apoptotic and later-stage cells (Fig. 1E).
Treatment with tunicamycin for 24 h led to shrinkage and
condensation of nuclei, and to positive staining with YO-PRO-1
dye (Fig. 1E). Treatment with SUN N8075 at 3 mM reduced the
tunicamycin-induced morphological changes in the nuclei and the
number of cells stained with YO-PRO-1 (Fig. 1E). The number of
cells exhibiting YO-PRO-1 fluorescence was counted, and the
positive cells were expressed as the percentage of YO-PRO-1- to
Hoechst 33342-positive cells (Fig. 1E). Twenty-four hours after the
treatment with tunicamycin, the percentage of YO-PRO-1-
positive cells was 47.163.5% (n=8), while in the control group,
the percentage (supplemented with 1% FBS) was 10.761.3%
(n=8). Treatment with SUN N8075 at 3 mM significantly reduced
the increase in YO-PRO-1-positive cells induced by tunicamycin.
Exposure to tunicamycin elevated the level of caspase-3 activity,
indicative of an early stage of ER stress-induced apoptosis [21]. To
determine the mechanism underlying the action of tunicamycin,
we examined the effect of SUN N8075 on the increases in cleaved
caspase-3 induced by treatment with tunicamycin. Tunicamycin
increased cleaved caspase-3 proteins (Fig. 1F), and pretreatment
with SUN N8075 at 10 mM significantly reduced the increase in
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SUN N8075 alone at 10 mM had little effect on the production of
cleaved caspase-3 (versus the vehicle-treated controls). SUN
N8075 has a potent antioxidant property [9], and therefore, the
protective effects of SUN N8075 on ER stress-induced cell death
may be derived from its antioxidative effect. However, antioxi-
dants, N-acetyl-cysteine (NAC) at 1 mM or edaravone at 1 to
10 mM, did not show any effects on the reduction of cell viability
after tunicamycin (Fig. S1A,B). Furthermore, NAC at 1 mM,
edaravone at 10 mM or trolox at 100 mM also did not inhibit the
reduction of cell viability after treatment with thapsigargin (Fig.
S1C). These data suggest that the protective effects of SUN N8075
on ER stress-induced cell death are mediated by a mechanism
other than antioxidant effect. On the other hand, SUN N8075 and
antioxidants both inhibited the reduction of cell viability in mouse
neuronal precursor cells (RGC-5) after serum deprivation or
intrinsic oxidative stress induced by L-buthionine-(S,R)-sulfox-
imine (BSO) plus glutamate, suggesting that SUN N8075
protected cell damage against other stresses depending on the
antioxidative effect (Fig. S2).
Gene expression analyses
ER stress activates signaling pathways, including the unfolded
protein response (UPR) that counteracts the effects of the original
stress. BiP acts as an ER-resident molecular chaperone that is
induced by ER stress, and this protein refolds the unfolded
proteins, thereby tending to maintain homeostasis in the ER
[22,23]. C/EBP-homologous protein (CHO) is a member of the
CCAAT/enhancer-binding protein family that is induced by ER
stress and participates in ER-mediated apoptosis [24]. UPR is
mediated by three types of ER transmembrane proteins: inositol-
requiring protein-1 (IRE1), RNA-dependent protein kinase–like
ER eukaryotic translation initiation factor 2a kinase (PERK), and
activating transcription factor 6 (ATF6) [1], and expression of both
BiP and CHOP mRNAs are upregulated by activation of these
pathways. To determine whether SUN N8075 can affect the UPR
after ER stress, BiP and CHOP mRNAs was quantitated with real-
time PCR. Tunicamycin induced BiP and CHOP expression in a
time-dependent manner (Fig. S3). SUN N8075 at a concentration
of 3 mM did not show any effects on these increases after treatment
with tunicamycin (Fig. S3). Furthermore, we examined cell
viability and protein expression of ATF4, BiP and CHOP after
tunicamycin with or without SUN N8075 in RGC-5 (Fig. S4)).
SUN N8075 inhibited the reduction of cell viability induced by
tunicamycin (Fig. S4A), but it did not affect the expression of
ATF4, BiP, or CHOP protein at 24 h after tunicamycin treatment
(Fig. S4B). These data suggest that SUN N8077 does not affect the
UPRs themselves.
To generate gene expression profiles after treatment with SUN
N8075 or tunicamycin, we performed microarray analyses on
4644 K Agilent Human expression arrays by hybridizing RNA
from SH-SY5Y. At least more than 26,000 genes out of 41,000
gene probes on the array were detected in each sample, and a
representative scatter plot comparison in gene expression with
DNA microarray between SUN N8075 and vehicle control
treatments at 7 h is shown in Fig. 2A. Heat map representation
of the hierarchical clustering of 320 genes with at least 2-fold
changed expression in SH-SY5Y cells treated with SUN N8075 at
3 mM for 3, 7 and 13 h out of the top 10% of fluorescence
intensity in the non-treated control is shown in Fig. 2B and listed
in Table S2. In the 320 genes, we identified the VGF gene as a
candidate gene. The induction of VGF was also confirmed by real-
time RT-PCR (Fig. 2C,D). SUN N8075 at a concentration of
3 mM significantly increased the VGF mRNA level to more than 2-
fold during 13 h compared with the vehicle-treated control
(Fig. 2C). Furthermore, VGF mRNA levels were time-dependently
increased by tunicamycin, and the increase was significant for 12 h
(Fig. 2D). The tunicamycin-induced VGF mRNA upregulation was
potentiated by pretreatment with SUN N8075 at 3 mM (Fig. 2D).
VGF is a neurotrophin-inducible and activity-regulated gene
product expressing in the central and peripheral neurons, in which
it is processed into peptides and secreted [11,25]. VGF synthesis is
stimulated by brain-derived neurotrophic factor (BDNF), a critical
regulator of hippocampal development and function [26,27].
However, the expression of neurotrophins, including BDNF and
glial cell derived neurotrophic factor (GDNF), and neuropeptide Y
(NPY) was not affected by SUN N8075 alone or after tunicamycin
with or without SUN N8075 (Table 1). These results indicate that
SUN N8075-induced VGF expression is not mediated by
neurotrophins. On the other hand, SUN N8075 increased the
expression of the immediate early genes (IEGs), c-fos and early
growth response gene 1 (EGR1) but not cAMP response element-
binding protein 1 (CREB1)o rJUN (Table 1). IEGs are regulatory
transcription factors, which may promote VGF expression. Alder
et al. [11] reported that BDNF increases the expression of IEGs,
including c-fos and EGR1 at 20 min and VGF at 3 h, and they are
blocked by mitogen-activated protein kinase kinase (MEK)
inhibitor or Ca
2+-calmodulin-dependent protein kinase II (CaM-
KII) inhibitor. These findings suggest that SUN N8075 may
induce VGF by regulating mitogen-activated protein kinase
(MAPK) or CaMKII activity. On the other hand, almost all the
15 ER-related genes listed in Table S3 were increased after being
treated with tunicamycin, but SUN N8075 did not affect the
expression of ER-related genes, suggesting that SUN N8075 could
not act on the UPRs themselves.
Requirement of VGF expression for the protective effects
of SUN N8075 on ER stress-induced cell death
We tested the involvement of VGF in the protective effect of
SUN N8075 on ER-induced cell death in SH-SY5Y cells. As
shown in Fig. 3A and 3B, the VGF siRNA completely abolished
the protective effect of SUN N8075 against tunicamycin-induced
cell death. Furthermore, VGF siRNA aggravated tunicamycin-
induced cell death compared with the control siRNA (Fig. 3B),
suggesting that endogenous VGF protects cells under ER stress. In
this condition, VGF siRNA decreased the VGF mRNA to 60% of
the control (Fig. 3C). On the other hand, overexpression of VGF
transiently transfected VGF plasmid vector inhibited cell death
induced by tunicamycin compared with the empty vector-
transfected control (Fig. 3D,E). These results strongly suggest that
the protective effect of SUN N8075 on tunicamycin-induced cell
death is mediated by the expression of endogenous VGF.
Furthermore, this is the first report to demonstrate that VGF
overexpression protects against ER stress-induced cell death.
SUN N8075 activates cell survival signals
VGF is upregulated by BDNF through extracellular signal-
regulated protein kinase (ERK)-dependent phosphorylation of the
nuclear transcription factor cAMP-response element binding
protein 1 (CREB1) in primary cultures of hippocampal neurons
[11]. Furthermore, BDNF protects neurons against apoptotic cell
death through MEK/ERK and phosphatidylinositol 3-kinase
(PI3K)/Akt pathways [28]. Activations of endogenous Akt and
MEK/ERK also control cell survival during ER stress by directly
counteracting ER stress [29]. Here we measured the phosphor-
ylation levels of Akt (p-Akt) and ERK1/2 (p-ERK1/2) after SUN
N8075 treatment or after tunicamycin treatment with or without
SUN N8075. SUN N8075 increased p-Akt levels in a time- and
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tunicamycin treatment for 24 h slightly reduced both pAkt and
p-ERK1/2 (Fig. S5C,D). SUN N8075 inhibited the dephosphor-
ylations of p-Akt and p-ERK1/2 at 24 h after treatment with
tunicamycin (Fig. S5C,D). ER stress activates survival signals such
as PI3K/Akt and MEK/ERK pathways in parallel with the UPR.
Hu et al. [29] reported that Akt and ERK are activated for up to
4 h after tunicamycin or thapsigargin stimulation, and their
activation is eliminated thereafter. Furthermore, Akt or MEK1
inhibition sensitized cells to ER stress-induced cell death [29]. In
the present study, a PI3K inhibitor (LY294002; 20 mM) or
MEK1/2 inhibitor (U0126; 5 mM) reduced cell viability, and
sensitized cells to ER stress-induced cell death (Fig. S5E,F).
Furthermore, the protective effect of SUN N8075 was attenuated
by the pretreatment with a PI3K inhibitor (LY294002; 20 mM) or
MEK1/2 inhibitor (U0126; 5 mM) (Fig. S5E,F). These data
suggest that SUN N8075 enhances survival signals such as PI3K/
Akt and MEK/ERK pathways. As mentioned above, VGF may
be upregulated by ERK-dependent phosphorylation of CREB1 or
induction of other IEGs including c-fos and EGR1 after SUN
N8075.
Motor dysfunction and survival in ALS models
To confirm the effects of SUN N8075 on motor dysfunction and
the survival of the familiar ALS model, we used two types of
transgenic animals overexpressing mutated human SOD1 genes:
transgenic mice overexpressing mutated (glycine to alanine in
position 93) human SOD1 (G93A) [16] and transgenic rats
overexpressing mutated (histidine to arginine in position 46)
human SOD1 (H46R) [17]. Treatment with SUN N8075 was
started when the G93A mice were 10 weeks old and the H46R rats
were 15 weeks old before each disease onset.
In the G93A mice, motor performance was tested by a rotarod
test (Fig. 4A). Vehicle-treated G93A mice began to show a decline
in motor performance around the age of 100 days that continued
to be gradually impaired thereafter; the mice were unable to
perform the test around the age of 130 days. Treatment with SUN
N8075 (30 mg/kg/day s.c.) prolonged the decline of latency to fall
off the rod. Kaplan–Meier life curves suggested that treatment
with SUN N8075 prolonged disease onset (p=0.024) and survival
(p=0.0351) in the G93A mice (Fig. 4B,C). In the G93A model
mice, the mean survival days of the vehicle-treated and the SUN
N8075-treated mice were 122.864.0 (n=12) and 136.263.4
(n=12), respectively (Fig. 4C). Treatment with SUN N8075
significantly prolonged the mean lifespan by 10.9% (p=0.0178) in
the G93A mice compared with that in the vehicle-treated G93A
mice. On the other hand, there was no significant difference in the
course of body weight between the SUN N8075-treated and the
vehicle-treated G93A mice (Fig. S6A).
Next, we used SOD1 H46R mutant rats as other types of
familial ALS models to evaluate the effects of SUN N8075 on
motor dysfunction and survival. H46R is one of 119 known SOD1
mutations that cause familial ALS, and H46R rats are character-
ized by initial muscle weakness and atrophy in the legs, very long
clinical courses and include many neuropil aggregates that lack
vacuoles [30]. In the H46R rats, the motor score was determined
by a 5-point motor score system (Fig. 4D). The vehicle-treated
H46R rats began to show a decline in motor performance around
the age of 170 days that continued to be gradually impaired
thereafter; the mice were unable to perform the test around the
age of 220 days. Treatment with SUN N8075 (10 mg/kg/day s.c.)
prolonged the decline of the motor score. Kaplan–Meier life
curves suggested that treatment with SUN N8075 prolonged
disease onset (p=0.012) and survival (p=0.011) in H46 rats
Table 1. Gene expression of VGF, neurotrophins and gene transcription factors in SH-SY5Y cells after SUN N8075 and during ER
stress with or without SUN N8075.
Fold change (vs. control)
6 h after Tm 12 h after Tm
Gene Genbank Time after SUN N8075 Vehicle SUN Vehicle SUN
Symbol Accession 3 h 7 h 13 h 7 h 7 h 13 h 13 h
VGF NM_003378 1.25 1.94 2.21 1.12 2.72 2.43 6.78
NPY NM_000905 1.22 1.43 1.64 0.57 0.84 0.82 1.20
BDNF NM_170735 0.82 0.85 0.94 0.86 0.69 0.58 0.58
GDNF AJ001898 1.12 1.04 0.93 0.91 0.84 0.91 0.89
FOS NM_005252 2.42 1.67 1.76 1.01 3.29 1.14 1.86
EGR1 NM_001964 2.75 1.93 1.73 2.61 11.19 1.15 2.63
JUN NM_002228 0.72 1.00 0.94 2.63 2.26 2.02 1.86
CREB1 NM_134442 1.08 1.09 1.02 1.04 1.21 0.87 0.95
SUN N8075 at a concentration of 3 mM was treated for 3, 7 or 13 h. One hour before tunicamycin treatment, SUN N8075 was treated, then tunicamycin was treated for 6
(7 h after SUN) or 12 h (13 h after SUN). VGF: VGF nerve growth factor inducible, NPY: Neuropeptide Y, BDNF: Brain-derived neurotrophic factor, GDNF: Glial cell derived
neurotrophic factor, FOS: c-fos proto-oncogene, EGR1: Early growth response protein 1, JUN: Jun oncogene, CREB1: cAMP responsive element binding protein 1, SUN:
SUN N8075, Tm: tunicamycin.
doi:10.1371/journal.pone.0015307.t001
Figure 2. Changes in the gene expression of SH-SY5Y cells after SUN N8075 treatment. (A) Representative scatter plot comparison in
gene expression with DNA microarray between SUN N8075 and vehicle control treatments at 7 h. (B) Heat map representation of hierarchical
clustering of 320 genes with at least 2-fold changed expression in SH-SY5Y cells treated with 3 mM of SUN N8075. The columns and rows represent
samples from the time-course study and individual gene expression levels, respectively. Shades of red indicate elevated expression while shades of
blue indicate decreased expression relative to the median (see the color scale). (C, D) Quantitative analysis of VGF mRNA after SUN N8075 (C), and
after treatment with tunicamycin with or without SUN N8075 (D).
doi:10.1371/journal.pone.0015307.g002
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vehicle-treated and SUN N8075-treated rats were 201.164.7
(n=9) and 214.762.0 (n=10), respectively (Fig. 4F, Table S4).
Treatment with SUN N8075 significantly prolonged the mean
lifespan by 6.7% (p=0.012) in the H46R rats compared with that
in the vehicle-treated H46R rats. On the other hand, there was no
significant difference in the course of body weight between the
SUN N8075-treated and the vehicle-treated H46R rats (Fig. S6B).
In this study, SUN N8075 was administered by subcutaneous
injection at 30 mg/kg for mice and at 10 mg/kg for rats, and the
maximum concentrations in plasma were approximately 2 mM
and 1 mM, respectively (Tamura S. et al., unpublished data). In the
present study, SUN N8075 at concentrations of 1 mM or higher
inhibited ER stress-induced cell death in vitro. Taken together,
these results show that SUN N8075 could delay disease onset and
prolong survival in different two types of familial ALS models.
Motor neuron loss and VGF expression in the spinal cords
of G93A ALS mice and sporadic ALS patients
We evaluated the effect of SUN N8075 on motor neuron loss in
the spinal cords of G93A mice at 14 weeks of age. The number of
motor neurons in the lumbar anterior horn of the G93A mice was
decreased to 59% of their wild-type (WT) littermates (Fig. 5A).
Treatment with SUN N8075 (30 mg/kg, s.c./day) in the G93A
mice significantly increased the number of surviving motor
neurons compared with that in the vehicle-treated G93A mice
(Fig. 5A). Recent studies revealed that a lowering VGF-derived
4.8 kDa fragment was identified in the CSF from patients with
ALS [31] and that VGF content was decreased in the CSF of ALS
patients and in the CSF, serum and spinal cord motor neurons of
G93A mice [13]. In the present study, we used immunohisto-
chemistry (Fig. 5B) and Western blotting (Fig. 5C) to assess the
expression of the VGF protein in the spinal cord. A large number
Figure 3. VGF protects cells against ER stress-induced SH-SY5Y cell death. (A) Representative fluorescence microscopy showing nuclear
stainings for Hoechst 33342 (blue) and propidium iodide (green) on SHSY-5Y cells transfected VGF siRNA or control siRNA at 24 h after tunicamycin
(TM) treatment with or without SUN N8075 (SUN). (B) The number of cells displaying fluorescence was counted, and positive cells were expressed as
the percentage of propidium iodide to Hoechst 33342. Each column represents the mean 6 S.E.M. (n=6). #p,0.05, ** and ##p,0.01 versus
relevant control group. (C) VGF siRNA transfection reduced the VGF mRNA level in SH-SY5Y cells. Each column represents the mean 6 S.E.M. (n=6).
**p,0.01 versus control group. (D, E) VGF overexpression inhibited cell deathinduced by tunicamycin. *p,0.05 versus TM plus empty vector-
transfected control control group.
doi:10.1371/journal.pone.0015307.g003
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the WT littermates (Fig. 5B). VGF immunoreactivity was
markedly decreased in the spinal cords of GA93A mice compared
with that in their WT littermates, and the reduction was
significantly ameliorated by treatment with SUN N8075. Western
blot analysis also revealed that a single VGF band at approxi-
mately 90 kDa was identified, and the band intensity in the spinal
cord of the G93A mice was significantly decreased to 58% of that
of the WT mice (Fig. 5C). Treatment with SUN N8075 inhibited
the decrease in the VGF band intensity in the spinal cords of the
G93A mice (Fig. 5C). Furthermore, we used double-immunoflu-
orescent staining to determine VGF localization in the lumbar
anterior horn of the spinal cord (Fig. 5D). VGF colocalized with
NeuN-positive motoneuron (.25 mm diameter) but not GFAP (an
Figure 4. Effects of SUN N8075 on motor dysfunction, disease onset and survival in two types of familial ALS model animals. (A–C)
G93A mutant SOD1 mice; effects of SUN N8075 at 30 mg/kg/day, s.c., on motor performance evaluated by the rotarod test (A), cumulative probability
of the onset of motor deficit (B), and survival (C) in G93A mutant SOD1 mice. (D–F) H46R mutant SOD1 rats; effects of SUN N8075 at 10 mg/kg/day,
s.c., on the motor performance score (D), cumulative probability of the onset of motor deficit (E), and survival (F) in H46R mutant SOD1 rats.
doi:10.1371/journal.pone.0015307.g004
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and sporadic ALS patients. (A) cresyl violet staining, (B) VGF immunostaining, (C) VGF immunoblotting, and its double-immunostainings, (D) with
GFAP (activated astrocyte marker), NeuN (neuronal marker) or GD11b (activated microglial marker). Scale bars =50 mm. Each column represents the
mean 6 S.E.M. (n=6). *p,0.05, ** and ##p,0.01 versus the relevant control group. (E) Human spinal cord tissue section. Representative
photographs are shown for the anterior horns of the spinal cords in the control patients and the patients with sporadic ALS. Scale bar =100 mm.
Average density of VGF immunoreactivity in the anterior horn of the human spinal cord. Each column represents the mean 6 S.E.M. (n=6). *p,0.05,
**p,0.01 versus control.
doi:10.1371/journal.pone.0015307.g005
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positive glial cells in the lumbar anterior horn of the WT littermates
(Fig. 5D). On the other hand, in the lumbar anterior horns of the
G93A mice, VGF-immunoreactive signals colocalized with GFAP-
positive astrocytes in addition to motor neurons but not the CD11b-
positive glial cells (Fig. 5D). These data indicate that VGF
expression is reduced in the spinal cords of the G93A mice, and
the decrease is ameliorated by the treatment with SUN N8075. As
mentioned above, the VGF level has been reported to be decreased
intheCSFofALSpatients compared withnormal subjects[13], but
there is no evidence of the decrease in VGF in the spinal cords of
ALS patients. In the present study, the expression level of VGF in
postmortem spinal cords of sporadic ALS patients was markedly
down-regulated, but typically expressed at high levels in the spinal
cords of the control patients in any sections cervical 7 (C7), thoracic
8(T8),and lumbar4(L4),respectively(Fig.5E).ThedensityofVGF
immunoreactivity was significantly lower in the lumbar anterior
horns of sporadic ALS patients than those in control patients with
other diseases (0.4060.09, 0.4660.14, and 0.5760.12 of the
control in sections C7, T8, and L4, respectively, n=6) (Fig. 5E).
These data suggest that the decrease in VGF in the spinal cord is
involved in ALS pathogenesis.
Gene expression profiles and glial activation in the spinal
cords of G93A ALS mice
To generate gene expression profiles on the spinal cords of WT
or G93A mice aged 14 weeks after SUN N8075 treatment, we
performed microarray analyses on 4644 K Agilent Mouse
expression arrays. At least more than 27,000 genes out of
41,000 gene probes on the array were detected in each sample,
and the Volcano plot of the probe data set averages of gene
expression in the spinal cords of the G93A mice (n=4) compared
with the WT mice (n=4) is shown in Fig. S7A. Seven hundred and
twelve genes (green and red squares) were considered statistically
significant between the G93A and WT mice based on the criteria
of the average fold-change (FC) $2, p#0.01 with the Benjamini-
Hochberg correction. A heat map representation of the hierar-
chical clustering of the 712 different gene expressions in the spinal
cords of G93A mice treated with or without SUN N8075 (each
group: n=4) compared with WT mice (n=4) is shown in Fig. S7B.
The gene expression profiles were apparent differences between
SUN N8075 and vehicle treatments in the G93A mice, and a
principal component analysis (PCA) component 1 discriminated
significantly among the 3 groups (Fig. S7C). We analyzed the gene
ontology classification for each category from the 712 different
genes and listed the top 10 categories in Fig. S7D. Almost all
categories included immune response genes. In particular, high
intensity and variant genes (signal .1000, FC.5) were astrocyte-
or microglia-related genes such as GFAP and CD11b/11c. Hence,
the activation of astrocytes and microglia was determined in the
spinal cords of the G93A mice using the immunohistochemical
technique. The number of GFAP-positive astrocytes and Iba-1-
positive microglia was significantly increased in the lumbar
anterior horns of the G93A mice compared with those in their
WT littermates (Fig. 6A,B). Treatment with SUN N8075 (30 mg/
kg, s.c./day) significantly decreased the number of both types of
glial cells in the spinal cords of the G93A mice compared with
those in the vehicle-treated G93A mice (Fig. 6A,B).
Discussion
Our results showed that SUN N8075 markedly protected
against ER stress-induced cell death in SH-SY5 cells at 1 mMo r
higher concentrations, and the protective effects are mediated by
endogenous VGF production. SUN N8075 increased VGF
expression as identified by microarray and secondary validation
approaches. VGF synthesis is also stimulated by BDNF through
ERK-dependent phosphorylation of CREB [26,27]. However,
SUN N8075 did not enhance BDNF mRNA, suggesting that its
VGF mRNA expression is not mediated indirectly by BDNF. On
the other hand, SUN N8075 gradually increased the phosphor-
ylation of ERK1/2 and Akt during the course of 24 h. These
findings suggest that ERK-dependent phosphorylation of CREB1
Figure 6. Effects of SUN N8075 on the glial activation in the spinal cords of SOD1G93A mice. G93A mice aged at 14 weeks-old increased
the number of GFAP-positive astrocytes (A) and Iba-1-positive microglial cells (B) in spinal cord, and their increases were abolished by SUN N8075
treatment. Scale bars =50 mm. Each column represents the mean 6 S.E.M. (n=6). *p,0.05, **p,0.01 versus WT mice.
doi:10.1371/journal.pone.0015307.g006
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gene expression by SUN N8075. Several types of VGF-derived
peptides have been detected in the rat brain, bovine pituitary and
human cerebrospinal fluid [32,33,34,35], and these peptides
possess multiple biological activities, autonomic activation, anti-
depression, enhancement in synaptic plasticity, penile erection and
increases in energy expenditure [11,36,37,38]. Recently, Severini
et al. [39] reported that TLQP-21, a naturally occurring VGF-
derived C-terminal peptide, protects rat cerebellar granule cells
against apoptosis induced by serum and K
+ deprivation, and that
TLQP-21 also increased the phosphorylation levels of ERK1/2
and Akt. Furthermore, a MEK1/2 inhibitor completely attenuat-
ed the protective effect of TLQP-21 on K
+ deprivation-induced
cell damage [39]. These findings support the idea that endogenous
VGF induced by SUN N8075 may activate survival signals via the
MEK/ERK and PI3K/Akt pathways.
A wide range of mechanisms are thought to be implicated in the
pathogenesis of ALS, including mitochondrial dysfunction,
excitotoxicity, oxidative stress, protein misfolding, proteosomal
dysfunction, aberrant growth factor signaling, inflammatory
process and glial activation [40,41]. On the other hand, the
accumulated evidence indicates that ER stress plays a role in the
pathogeneses of familial and sporadic ALS [4,5,6], and therefore,
they may have a common mechanism for motorneuron loss
through ER stress as downstream signaling pathways. In the
present study, extrinsic VGF expression protected against ER
stress-induced cell death in SH-SY5Y cells. Furthermore, VGF
was markedly decreased in the spinal cords of the GA93A mice
compared with that in their WT littermates in agreement with a
previous report [13], and the reduction was significantly
ameliorated by the treatment with SUN N8075. Zhao et al. [13]
also reported that exogenous VGF expression by adenoviral
mouse VGF transfection in the primary spinal cord neurons from
SOD1 G93A mice has been reported to protect neurons against
AMPA- or NMDA-mediated excitotoxic injury. Furthermore, we
demonstrated for the first time that the VGF level was lower in the
spinal cords of sporadic ALS patients than in the control patients.
Taken together, VGF depletion may participate in disease onset
and/or progression of ALS.
In conclusion, we demonstrated that SUN N8075 inhibits ER-
stress-induced neuronal cell death via VGF expression and that
VGF plays a critical role in motor neuron survival. Accordingly,
VGF may be a potential new therapeutic target for neurodegen-
erative disorders, including ALS.
Supporting Information
Methods S1 Supplemental Materials and Methods for Supple-
mental Figures and Tables were addressed.
(PDF)
Figure S1 Anti-oxidative agents do not reveal protective effects
on ER stress-induced SH-SY5Y cell death. (A) Edaravone at 1 to
10 mMo r( B) N-acetyl-cystein (NAC) at 1 mM did not show any
effects on the reduction of cell viability at 24 h after tunicamycin
treatment. (C) Edaravone (Eda) at 10 mM, NAC at 1 mM or trolox
(Tro) at 100 mM did not inhibit the reduction of cell viability at
24 h after thapsigargin treatment.
(TIF)
Figure S2 SUN N8075 and anti-oxidative agents protect cell
death induced by serum devrivation, or oxidative stress in RGC-5
cells. (A) SUN N8075 (SUN) at 0.1 to 1 mM, edaravone (Eda) at
10 mM, and trolox at 100 mM show protective effect on the
reduction of cell viability at 48 h after serum deprivation. Each
column represents the mean 6 S.E.M. (n=6). ##p,0.01 versus
control. **p,0.01 versus serum deprivation alone. (B) SUN N8075
(SUN) at 0.1 to 1 mM and trolox at 100 mM show protective effect
on the reduction of cell viability at 24 h after L-buthionine-(S,R)-
sulfoximine (BSO; 0.5 mM) plus glutamate (10 mM). Each
column represents the mean 6 S.E.M. (n=6). ##p,0.01 versus
control. **p,0.01 versus BSO plus glutamate alone.
(TIF)
Figure S3 SUN N8075 does not affect gene expression level of
BiP or CHOP on SH-SY5Y cells after tunicamycin. BiP and CHOP
mRNA levels were measured using a quantitative real-time PCR.
(TIF)
Figure S4 SUN N8075 protect cell death induced by tunica-
mycin, but did not affect protein expression of ATF4, BiP or
CHOP in RGC-5 cells. (A) SUN N8075 at 0.1 to 3 mM shows
protective effect on the reduction of cell viability at 24 h after
tunicamycin at 2 mg/ml. Each column represents the mean 6
S.E.M. (n=8). ##p,0.01 versus control. **p,0.01 versus
tunicamycin alone. (B) ATF4, BiP and CHOP protein levels were
measured using Western blotting.
(TIF)
Figure S5 SUN N8075 enhances survival signals via Akt and
ERK1/2 activations. (A) Time-course of changes in phosphor-
ylated-Akt level after SUN N8075 treatment. (B) Concentration-
dependent changes in phosphorylated-Akt level at 24 h after SUN
N8075 treatment. (C, D) Tunicamycin reduced phosphorylated-
Akt (C) and phosphorylated-ERK1/2 (D) levels, and their
reductions were ameliorated by SUN N8075 treatment. (E, F)
The protective effect of SUN N8075 on tunicamycin-induced
reduction of cell viability was eliminated by LY294002, a
PI3kinase inhibitor, at 20 mM( E) or U0126, a MEK1/2 inhibitor,
at 5 mM( F).
(TIF)
Figure S6 Effects of SUN N8075 on body weight changes in two
type of familial ALS model animals. (A) Effect of SUN N8075 at
30 mg/kg/day, s.c. on body weight change in G93A mutant
SOD1 mice. (B) Effect of SUN N8075 at 10 mg/kg/day, s.c. on
body weight change in H46R mutant SOD1 rats.
(TIF)
Figure S7 (A) Volcano plot of probe data set averages of gene
expressions in the spinal cords of G93A (n=4) compared with WT
(n=4). The x-axis and y-axis correspond to the average fold-
change (FC), and the negative log10-transformed p value between
G93A and WT mice, respectively. Green (FC $2, 0.01#p#0.05)
and red (FC $2, p#0.01) squares represent significantly
differentially expressed probe sets, and gray squares represent
probe sets with no significant difference between G93A and WT
mice. The changes in gene expression were considered statistically
significant based on the criteria of FC $2, p#0.01 with
Benjamini-Hochberg correction. (B) Heat map representation of
hierarchical clustering of 712 different gene expressions in the
spinal cords of G93A compared with WT mice. The columns and
rows represent the tissue samples (WT = Blue, G93A = red,
G93A + SUN N8075 = yellow) and individual gene expressions,
respectively. Shades of red indicate elevated expression while
shades of blue indicate decreased expression relative to the median
(see the color scale). (C) Principal components analysis (PCA) in the
spinal cord of WT, G93A and G93A + SUN N8075 treated mice.
Differently expressed 712 genes in the two groups (WT vs. G93A
mice) were analyzed using a principal component analysis, and the
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81.23%, 6.99%, and 3.90%, respectively. The results are
expressed as a one-dimensional function with PCA component 1
that defines the direction of greatest variation in the probe/gene
transcriptomic feature space. ##p,0.01, *p,0.05, Student’s t-
test. (D) Gene ontology classification for each category from the
712 different genes.
(TIF)
Table S1 Clinical information about the spinal cord tissues from
patients with sporadic ALS (a) and for control (b). M, male; F,
female; PMI, post mortem interval; y, years; m, months; h, hours.
(PDF)
Table S2 Gene expression profiles after SUN N8075 treatment
in SH-SY5Y cells.
(PDF)
Table S3 Gene expression profiles for ER-stress responsible
genes after SUN N8075 alone, or tunicamycin with or without
SUN N8075 in SH-SY5Y cells. q: two-fold or more increase, R:
no changes.
(PDF)
Table S4 SUN N8075 prolongs disease onset and lifspan in a rat
model of familial ALS. Data are the means 6 S.E. (n=9 or 10),
*P ,0.05 vs vehicle-treated ALS mouse group. a Observable
functional deficits (motor score of 4), b Righting reflex failure
(motor score of 1), c Motor score of 0.
(PDF)
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